The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Nov 2023 17:56

RNS Number : 4035S
Instem plc
03 November 2023

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B3TQCK30

Issuer Name

INSTEM PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Sand Grove Capital Management LLP

City of registered office (if applicable)

Country of registered office (if applicable)

GB

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

02-Nov-2023

6. Date on which Issuer notified

03-Nov-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

9.250000

0.810000

10.060000

2302906

Position of previous notification (if applicable)

6.020000

0.210000

6.230000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B3TQCK30

2117730

9.250000

Sub Total 8.A

2117730

9.250000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

EQUITY CFD

Cash

185176

0.810000

Sub Total 8.B2

185176

0.810000%

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

03-Nov-2023

13. Place Of Completion

London, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUOVBROVUARAA
Date   Source Headline
15th May 20237:00 amRNSTransfer of ToxHub Platform and launch of Centrus®
11th May 20233:26 pmRNSHolding(s) in Company
11th May 20237:00 amRNSUS Government Contract Award
4th May 20235:07 pmRNSHolding(s) in Company
3rd May 20237:00 amRNSNotice of Results and Investor Presentation
2nd May 20234:13 pmRNSExercise of Options, Issue of Equity & TVR
14th Apr 20234:38 pmRNSHolding(s) in Company
13th Mar 20237:30 amRNSNo Exposure to Silicon Valley Bank
31st Jan 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSAppointment of Independent Non-Executive Director
5th Jan 20237:00 amRNSExercise of Options, Director/PDMR Dealing & TVR
22nd Dec 20227:00 amRNSContract Extension with Leading CRO
30th Nov 20225:48 pmRNSHolding(s) in Company
12th Oct 20227:00 amRNSExercise of Options, Issue of Equity and TVR
27th Sep 20227:01 amRNSHalf-year Report
27th Sep 20227:00 amRNSSettlement of Historical Licence Dispute
13th Sep 20227:00 amRNSNotice of Results and Investor Presentation
9th Sep 20223:49 pmRNSHolding(s) in Company
2nd Sep 20227:00 amRNS$12m five-year agreement with Leading CRO
4th Aug 20227:00 amRNSHalf Year Trading Update
29th Jun 20225:03 pmRNSHolding(s) in Company
9th Jun 20224:01 pmRNSResult of AGM
20th May 20224:31 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of AGM & Posting of Annual Report
3rd May 202212:00 pmRNSHolding(s) in Company
3rd May 20227:00 amRNSEuropean Medicines Agency Research Grant
26th Apr 20224:40 pmRNSSecond Price Monitoring Extn
26th Apr 20224:35 pmRNSPrice Monitoring Extension
26th Apr 202210:15 amRNSEarn Outs and Deferred Payments
26th Apr 20229:54 amRNSFinal Results
26th Apr 20227:00 amRNSAnnouncement re: full year results
20th Apr 20229:05 amRNSNotice of Results & Investor Presentation
15th Mar 20221:49 pmRNSGrant of PDMR Options
14th Mar 20225:29 pmRNSExercise of Options, Issue of Equity and TVR
14th Mar 202211:22 amRNSHolding(s) in Company
22nd Feb 202210:15 amRNSHolding(s) in Company
4th Feb 20228:08 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSTrading Update
11th Jan 20227:00 amRNSAppointment of Joint Broker
21st Dec 20217:00 amRNSH2 China Market Update
13th Dec 20214:55 pmRNSHolding(s) in Company
22nd Nov 20212:33 pmRNSHolding(s) in Company
22nd Nov 20217:00 amRNSNew In Silico Software Release
11th Oct 20213:15 pmRNSDirector/PDMR Shareholding
29th Sep 202110:34 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSDirectorate Change
28th Sep 20217:00 amRNSGrant of PDMR Options
27th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSNotice of Results and Investor Presentation
14th Sep 20217:00 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.